- Research
- Open access
- Published:
Incidence, distribution, disease spectrum, and genetic deficits of congenital heart defects in China: implementation of prenatal ultrasound screening identified 18,171 affected fetuses from 2,452,249 pregnancies
Cell & Bioscience volume 13, Article number: 229 (2023)
Abstract
Background
Congenital heart defects (CHDs) are the most common birth defects. Assessment of the incidence, distribution, disease spectrum, and genetic deficits of fetal CHDs in China is urgently needed.
Methods
A national echocardiography screening program for fetal CHDs was implemented in 92 prenatal screening–diagnostic centers in China.
Findings
A total of 18,171 fetal CHD cases were identified from 2,452,249 pregnancies, resulting in 7·4/1,000 as the national incidence rate of fetal CHD. The incidences of fetal CHD in the six geographical regions, the southern, central, eastern, southwestern, northern, and northwestern, were 7·647 (CI: 7·383–7·915), 7·839 (CI: 7·680–8·000), 7·647 (CI: 7·383–7·915), 7·562 (CI: 7·225–7·907), 5·618 (CI: 5·337–5·906), and 4·716 (CI: 4·341–5·108), respectively, per 1,000 pregnancies. Overall, ventricular septal defect was the most common fetal CHD, accounting for 17.04% of screened pregnancies nationwide, and tetralogy of Fallot, the most common anomaly in the major defect of fetal CHD, was the second most common, accounting for 9.72%. A total of 76.24% cases of fetal CHD were found to be an isolated intracardiac single defect. The remaining 23.76% of cases of fetal CHD had multiple heart defects. Among all extracardiac malformations, the central nervous system (CNS) was the most common tissue with extracardiac anomalies associated with CHD, accounting for 22.89% of fetal CHD cases. Chromosomal karyotyping identified trisomy 18 as the most common chromosomal abnormality in fetal CHD. We also documented that CHD-containing syndromes could be identified with a comprehensive approach integrating prenatal ultrasound, MRI, pathological autopsy, and cytogenetics and molecular genetics.
Conclusion
Implementation of prenatal echocardiography as a practically feasible platform to screen fetal CHD will reduce the financial and emotional burden of CHD, which may facilitate intrauterine and neonatal intervention of CHD.
Background
Congenital heart defects (CHDs), which result from incomplete or abnormal development of the fetal heart during the early stage of pregnancy, are the most common type of birth defect (https://www.cdc.gov/ncbddd/birthdefects/index.html), affecting 8 to 12 per 1,000 liveborn infants and accounting for nearly one-third of all major congenital anomalies worldwide [1, 2]. In the United States, about 40,000 (1%) births per year are affected with CHD (https://www.cdc.gov/ncbddd/heartdefects/data.html). Several studies of the regional incidence of CHD in China have shown that the incidence of CHDs was similar to that in the global report, [2,3,4,5] except that the incidence could be as high as 38.1 per 1,000 live births in the ethnic minority of “Uygur” at Xinjiang Uygur Autonomous Region (AR), which is geographically adjacent to Russia [6]. CHDs may result from genetic deficits; however, unexplained CHDs could occur secondarily to noncoding genetic, epigenetic, and environmental factors, among others [7,8,9]. Such environmental factors include abnormal development and dysfunction of the placenta in pathological pregnancies of intrauterine growth retardation, preterm birth, stillbirth, and preeclampsia [10,11,12,13,14]. Application of transabdominal echocardiography ultrasonographic screening to evaluate for CHDs in clinical practice has increased the detection rate of CHDs [15, 16]. Because of its ability to detect CHDs non-invasively in the early stage of pregnancy, prenatal ultrasound screening has been implemented, along with prenatal hemodynamic screening, as a routine clinical procedure in prenatal healthcare management worldwide [17].
Prenatal screening for CHDs, along with birth defects, has been implemented in China, along with the implementation of a surveillance system for public healthcare and prenatal healthcare [18]. Thousands of prenatal ultrasound specialists have been trained in the nationally credentialed training centers and have been certified for qualification to conduct prenatal ultrasound screening, which ensures that a standardized procedure is applied in the multicenter practices. However, detailed information about the true incidence and disease spectrum of CHDs throughout China is lacking. Therefore, most reports of the incidence/ prevalence and disease spectrum of CHDs in China identified from newborns before 2015 ignored fetuses with CHD that were aborted. In this first Chinese national study of the incidence and disease spectrum of CHDs, 18,171 fetal CHDs were identified and documented via fetal echocardiography through prenatal ultrasound screening for CHDs from among 2,452,249 pregnancies.
Methods
Research design and ethics issue
This project was a multi-institutional clinical research investigation by the Chinese Consortium for Prenatal Ultrasound Screening of Congenital Heart Defects, with fetal echocardiography to determine the national incidence, distribution, spectrum, and genetic defects of fetal CHD. The procedures and protocols implemented were reviewed and approved by the Ethics Committees of Maternal and Child Health Hospital of Hubei Province. The research studies were coordinated by the Department of Diagnostic Ultrasonography at the Maternal and Child Health Hospital of Hubei Province. Informed consent was obtained from each pregnant participant. Ultrasound data between the period of January 1, 2011 and December 31, 2013 were collected as part of clinical procedures for prenatal healthcare management.
Implementation of prenatal screening of CHD with standardized procedures
As part of the ongoing national mandatory program to conduct nationwide surveillance for prevention of structural CHDs, the Ministry of Health (MOH)–credentialed National Prenatal Ultrasound Diagnostic Training Center (NPUDTC) initiated a training program in 2006 (Figure S1). A standardized operating procedure (SOP) for fetal echocardiography, following the guidelines of the International Society for Obstetrics and Gynecology (ISUOG) (http://www.ISUOG.org) and the American Institute of Ultrasound in Medicine (AIUM) Clinical Standards Committee, [19, 20] was provided to train prenatal ultrasound specialists. These trained specialists were capable of performing fetal ultrasound scan at the mid-trimester—optimally at between 18 and 22 weeks’ gestational age—with ultrasound skills for the four chambers, outflow tract including left ventricular outflow tract and right ventricular outflow tract, and three-vessel trachea views to capture and to recognize all types of CHD. Prenatal ultrasound specialists nationwide who graduated from and were certified by the NPUDTC for prenatal ultrasound screening of fetal CHD participated in this clinical research project among 93 prenatal screening-diagnostic centers (Table S1).
Prenatal screening for CHD
Instruments used for prenatal ultrasound screening in this study included Siemens Acuson Sequoia 512 and S2000 (Siemens Medical Solutions Inc., Mountain View, CA, United States), Voluson 730 Expert and Voluson E8 (GE Healthcare, Kretz Ultrasound, Zipf, Austria), Philips IU 22 (Philips Medical Systems, Bothell, WA, United States), and Samsung UGEO WS80 (Samsung Medison Co., Ltd., Korea). In each ultrasound screening center, at least one advanced ultrasound system was employed. The final imaging was reviewed and confirmed by two ultrasound experts. The raw data were then transferred from the ultrasound unit directly into an electronic database to avoid generation of any errors via manual data entry. Random audits were performed to verify data reliability and accuracy during data transfer.
Follow-up and confirmation
To verify the accuracy of prenatal ultrasound screening, positive cases determined by echocardiography were verified by postnatal follow-up with (1) clinical visits, (2) ultrasound and/or magnetic resonance imaging (MRI), (3) surgical observation, (4) pathological autopsy of aborted fetus, and (5) genetic studies.
Data collection
Demographic information about pregnancies was collected from hospital administrative records. Software with multiple drop-down menus for the purpose of data collection from multi-centers was developed at the NPUDTC. Interpretations of fetal heart malformations followed the ISUOG and AIUM Clinical Standards Committee guidelines and were coded on the basis of the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) [17, 19,20,21]. CHD cases were grouped as CHDs with intra-cardiac malformation and CHDs with extra-cardiac malformation. The intra-cardiac malformations were further subgrouped into single abnormalities and multi-abnormalities. For multi-abnormalities, if more than one cardiac malformation was observed, the major anomaly was counted into the subgroup.
Statistical analysis
All statistical analyses were performed using SPSS 13.0 software (SPSS Inc, Chicago, IL, USA) and Arcgis10.2. An unpaired t-test was used to compare incidence parameters among northern, central, eastern, western, and southern China. Categorical data were compared by using Pearson chi-square analysis. The relationship between incidence parameter and gross domestic product was assessed by simple linear regression analysis. p value of less than 0.05 was considered significant.
Results/ findings
Incidence of fetal CHD
A total of 18,171 fetuses affected with CHDs were identified from 2,452,249 pregnancies (Table S2) among 92 (67 tertiary, 22 secondary, and three primary) hospitals across 31 provinces/municipalities/ ARs (Table 1a). Collection of reliable data was not successful in the Tibet AR (labeled as Xizang in Fig. 1), due to incomplete prenatal screening. The overall nationwide incidence of fetal CHD, with the lack of the Tibetanese population, was 74·099/10,000 (18,171/ 2,452,249) pregnancies in China. The regional incidences of fetal CHD in the six geographical regions—the southern, central, eastern, southwestern, northern, and northwestern—were 76·47 (CI: 73·83–79·15), 78·39 (CI: 76·80–80·00), 76·47 (CI: 73·83–79·15), 75·62 (CI: 72·25–79·07), 56·18 (CI: 53·37–59·06), and 47·16 (CI: 43·41–51·08) per 10,000 pregnancies. The incidences of fetal CHD in the ocean coast provinces, including the regions in the south and east, and the province of Shandong but not the province of Fujian or Zhejiang, were relatively higher than those in inland areas (Fig. 1). In the non–ocean coast region, the incidence of CHD was below 9·0 per 1,000 pregnancies in all provinces except Shanxi, which has the highest rate of neuronal tube defects (NTDs) in China and in the world. [22].
Distribution of CHD
Subtypes of CHD in the major and minor anomalies and their presence in tertiary hospitals vs. in primary and secondary hospitals were documented (Table 1a). Overall, ventricular septal defect (VSD) was the most common fetal CHD, accounting for 17·04% of pregnancies screened nationwide. Tetralogy of Fallot (TOF), the most common anomaly in the major defect of fetal CHD, was the second most common after VSD, accounting for 9·72% of pregnancies. Following VSD and TOF, the incidences of CHD were atrioventricular septal defect (AVSD) (7·29%), double-outlet right ventricle (DORV) (5·09%), persistent left superior vena cava (PLSVC) (4·23%), transposition of the great artery (TGA) (3·82%), single ventricle (SV) (3·19%), hypoplastic left heart syndrome (HLHS) (2·83%), coarctation of the aortic arch/interrupted aortic arch (COA/IAA) (2·72%), and persistent truncus arteriosus (PTA) (2·71%). These CHDs comprised the top-10 most common fetal CHDs (Fig. 2).
Spectrum of all anomalies of CHD
The spectrum of CHD cases in China was determined to comprise 15 major and 21 minor anomalies (Table 1b). Among the 18,171 fetal CHD cases, 14,096 (76·24%) were isolated single defects within the heart, the top 5 most common of which were VSD (29·09%), TOF (14·43%), AVSD (10·24), PLSVC (7·36%), and TGA (4·51%). The remaining 4,075 (23·76%) cases had multiple heart defects, the top 5 most common of which were DORV (18·58%), SV (12·29%), COA/IAA (10·77%), TOF (8·59%), and AVSD (8·44%).
Rare anomaly of fetal CHD
In this study, we defined rare anomalies (RAs) as CHDs whose frequency is less than 1%, as presented in Table 1b. Among all fetal CHDs, 17 subtypes, including five subtypes of fetal CHD—total anomalous pulmonary venous drainage (0·44%), double-outlet left ventricle (DOLV) (0·18%), aortic atresia (AA) (0·14%), aortopulmonary window (0·13%), and ectopia cordis (0·13%)—among major anomalies, and 11 minor anomalies—Ebstein’s anomaly (0·69%), tricuspid atresia (TA) (0·22%), mitral valve stenosis (0·18%), coronary artery fistula (CAF) (0·13%), conjoined twins with one heart (CTOH) (0·09%), mitral atresia (MA) (0·08%), cor triatriatum (CT) (0·07%), ventricular aneurysm (VA) (0·06%), endocardial fibroelastosis (EFE) (0·06%), premature closure of the ductus arteriosus (PCDA) (0·04%), and cardiac diverticulum (CD) (0·02%)—were RAs. These RAs account for 3·44% (1·78% major anomalies and 1·66% minor anomalies) of CHD cases. Furthermore, seven subtypes (CTOH, MA, CT, VA, EFE, PCDA, and CD) whose frequencies were less than 0·1% may be classified as very rare anomalies (vRAs).
Fetal CHD accompanied with extracardiac defects
A total of 5,338 cases of fetal CHD were found to be accompanied by extracardiac malformation(s) and were labeled as extracardiac congenital heart defects (xCHDs). Sixteen subtypes of fetal CHD were identified and correlated with extracardiac malformations (Table 2). VSD was the most common xCHD, accounting for 30% (1,578/5,338) of total xCHDs. AVSD, TOF, and DORV were the next three most common xCHDs, accounting for 13·23% (706/5,338), 12·20% (651/5,338), and 12·14% (648/5,338), respectively. VSD accompanied with central nervous system (CNS) malformation was the most common complex birth defect involved in xCHD, as shown in Fig. 3, accounting for 8% of fetal CHD cases with xCHD (427/5,338). Among all extracardiac malformations, the CNS was the most common organ/tissue to accompany xCHD, accounting for 22·89% (1,222/5,338) of xCHD cases.
Genetic study of chromosomal abnormalities with karyotyping and microarray
Genetic study for chromosomal abnormality was performed among 566 cases of fetal CHD, 487 of which were analyzed by karyotyping, and 79 by microarray to determine chromosomal copy number variations (CNVs) including DNA fragment deletion and/or repetition/ duplication or uniparental disomy (UPD). As presented in Fig. 4; Table 3, the most common chromosomal abnormality in CHD is trisomy 18 (159/487, 32·65%), followed by trisomy 21 (138/487, 28·34%). When microarray was applied to identify chromosomal segment abnormalities (Table 4), 78·48% (62/79) of cases were found to carry pathogenic microdeletion, microrepetition/microduplication, UPD, or large-segment deletion or repetition. Twenty-two cases were the result of microdeletion, and three of microduplication of chromosome 22q. Twenty-five (of 62) CNVs, including seven in VSD, two in DORV, three in TOF, one each in AS, COA/IAA, hypoplastic right heart syndrome (HRHS), PLSVC, and PTA as well as six in complex CHDs involved in the chromosomal region 22q11 and two (HRHS, TOF) in 22q13, accounted for 40·32% of pathogenic CNVs. The remaining 17 CNVs were considered suspected pathogenic alleles, in which chromosomal deletion 16p11-12 was the predominant abnormality, accounting for 29·41% (5/17) of CNVs.
Termination of pregnancy as a consequence of prenatal screening of CHD
Among 12,441 CHD cases for which data were available, 60·69% (7,551/12,441) pregnancies were confirmed to have been selectively terminated. Of these aborted fetuses, 6,857 underwent postnatal pathological autopsy, which characterized 2,277 (33·21%) with intracardiac simple CHDs, 2,084 (30·39%) with intracardiac complex CHDs, and 2,308 (33·66%) with CHDs with extracardiac malformation(s), and 188 cases (2·74%) were independently identified as carrying chromosomal abnormalities. TOF was the most common CHD among the aborted fetuses, followed in descending order by AVSD, DORV, VSD, TGA, SV, PTA, HLHS, COA/IAA, and HRHS, as shown in Fig. 5.
Postnatal follow-up to verify the accuracy of prenatal ultrasound screening results
Prenatal ultrasound is a screening, rather than a diagnostic, procedure. In this study, postnatal follow-up was carried out for 20% (3,619) of 18,171 fetal CHD cases, including 1,965 cases by the postnatal diagnostic procedure(s) of clinical visits, imaging (chest X-ray, ultrasound, and/or MRI), and neonatal surgery; and 1,654 cases by pathological autopsy of aborted fetuses (Table 5). Our follow-up results showed 4·70% of cases with 100% agreement between prenatal screening results and postnatal verification, for the CHD subtypes of AA, CAF, dextrocardia, DOLV, ductus arteriosus stenosis, HLHS, HRHS, heterotaxy syndrome, MA, myocardiopathy, pulmonary atresia/VSD, PCDA, patent ductus arteriosus, pulmonary valvular stenosis, TA, tricuspid valve cleft, and tricuspid valve dysplasia. Other than three subtypes—two (aortic valve stenosis and noncompaction of the ventricular myocardium) that were completely misreported and 44 cases of COA/IAA that showed 45.45% agreement—the majority of the prenatal ultrasound results showed more than 60% agreement between prenatal screening results and postnatal follow-up confirmation. Overall, prenatal ultrasound resulted in 88% accuracy.
Discussion
Incidence and distribution
Applying prenatal ultrasound screening, we determined that the incidence of CHDs in China during 2011–2013 was 7·4099 per 1,000 (7·4099%) pregnancies. To our knowledge, this is the largest single cohort in the world, with 2,452,249 pregnancies reported so far. The incidence of Chinese fetal CHD cases in the current report is similar to that reported in Western countries (Table S3) [23,24,25,26]. The incidence is higher in advanced, developed regions, such as in the southeastern provinces of Shandong, Jiangsu, and Guangdong, where CHD incidence is ≥ 9% (Fig. 1), and in provinces with a high rate of birth defects, such as 9·8% in Shanxi province [22]. CHD incidence is much lower—below 6%—in the western provinces of Yunnan, Qinghai, Gansu, and Xinjian (Fig. 1). However, the higher incidence in coastal areas vs. the low rate in western developing regions appears not to be correlated with economic development (Figure S2).
Spectrum of CHDs: single vs. complex and intracardiac vs. extracardiac
A total of 36 subtypes of fetal CHD, including 15 major and 21 minor abnormalities, have been reported in this study. To our knowledge, this is the most complete collection of fetal CHD cases among Chinese populations. We determined that the most common single intracardiac anomaly was VSD, followed by TOF, AVSD, PLSVC, and TGA. Among the intracardiac multi-anomalies, DORV was the most common, followed by SV, COA/IAA, TOF, and AVSD. We also documented that the CNS was found to be the most commonly involved extracardiac tissue, accounting for 20·89% of extracardiac defects, followed by the urogenital (15·21%), craniofacial (13·52%), digestive (8·60%), and skeletal (7·99%) systems. Fetal appendage malformations (21·04%), fetal hydrops (8·29%), and fetal abdominal-wall defects (4·45%) were also found to occur commonly with intracardiac anomaly.
Genetics and genomics: Cytogenetics vs. molecular genetics
It has long been known that CHDs may result from chromosomal abnormalities. CHD in Down syndrome (DS, trisomy 21) and in DiGeorge syndrome, characterized by microdeletion of the DiGeorge critical region at 22q11.21, represents two traditional conditions [7, 8]. DS is by far the most common and the best-known disorder resulting from chromosomal aneuploidy and the most common cause of intellectual disability. CHD is the leading cause of mortality and morbidity during the first two years of life in the DS population [27]. DiGeorge syndrome is caused by the deletion of a small segment of chromosome 22 [28]. Advanced genetic studies have identified about 400 genes implicated in CHDs, encompassing transcription factors, cell signaling molecules, and structural proteins that are important for heart development [29]. In our study, we initiated chromosomal karyotyping to determine the aneuploidy, followed by microarray assay for CNVs (Tables 3 and 4), to identify chromosomal abnormalities among the fetal CHD cases identified through prenatal echocardiography. In this study, four cases of TOF showed micro-deletion at 22q11.21, which is characteristic of DiGeorge syndrome. Micro-deletion at this DiGeorge’s locus was also the most common abnormality in 53·84% of VSD cases. Genome-wide association study (GWS) was also performed, as presented in Fig. 6. One case was CHARGE syndrome, which was originally screened as AVSD with prenatal fetal echocardiography, diagnosed with MRI, confirmed by autopsy, and studied with GWS, which identified a c.6482del at gene CHD7 that produced a mutant peptide. The second example was a point mutation, c.309 C > A, at gene LZTR1, identified from a case of fetal TOF and determined to be Noonan syndrome.
Clinical application and data reliability
The overall 88% agreement in this study between prenatal ultrasound results and the follow-up confirmation (Table 5) demonstrates the feasibility and capability of performing a nation-wide study with a standardized procedure. Our experience is that system-wide training in general prenatal ultrasound skills and knowledge with on-site initiation of prenatal ultrasound screening to recognize fetal cardiac anomalies is critical for success. Whether the affected fetus is born or is terminated, postnatal follow-up may determine the accuracy of screening outcome, especially at early stages. This follow-up may help in implementation of prenatal screening for CHD in under-developed regions. In developed areas, we encourage clinicians to consider the comprehensive approach to confirmation of results from prenatal screening for CHD, integrating prenatal ultrasound, MRI, pathological autopsy, postnatal cardiac ultrasound or imaging, and genetic studies (Fig. 6), to better understand the molecular pathogenesis of CHD. With this approach, we will be able to explore and implement early intervention to prevent fetal CHD and to reduce the global burden of treatment for CHDs.
Abbreviations
- AA:
-
aortic atresia
- APW:
-
aortopulmonary window
- AVSD:
-
atrioventricular septal defect
- CAF:
-
coronary artery fistula
- CD:
-
cardiac diverticulum
- COA/IAA:
-
coarctation of the aortic arch/interrupted aortic arch
- CT:
-
cor triatriatum
- DOLV:
-
double-outlet left ventricle
- DORV:
-
double-outlet right ventricle
- EA:
-
Ebstein’s anomaly
- EC:
-
ectopia cordis
- EFE:
-
endocardial fibroelastosis
- HLHS:
-
hypoplastic left heart syndrome
- HRHS:
-
hypoplastic right heart syndrome
- MA:
-
mitral atresia
- PCDA:
-
premature closure of the ductus arteriosus
- PLSVC:
-
persistent left superior vena cava
- PTA:
-
persistent truncus arteriosus
- SV:
-
single ventricle
- TA:
-
tricuspid atresia
- TBS:
-
Taussig Bing syndrome
- TGA:
-
transposition of the great artery
- TOF:
-
tetralogy of Fallot
- VA:
-
ventricular aneurysm
- VSD:
-
ventricular septal defect
References
Hoffman JI, Kaplan S. The incidence of congenital Heart Disease. J Am Coll Cardiol. 2002;39:1890–900.
Wu W, He J, Shao X. Incidence and mortality trend of congenital Heart Disease at the global, regional, and national level, 1990–2017. Med (Baltim). 2020;99:e20593. https://doi.org/10.1097/MD.0000000000020593.
Yang XY, Li XF, Lü XD, Liu YL. Incidence of congenital Heart Disease in Beijing, China. Chin Med J (Engl). 2009;122:1128–32.
Zhao QM, Ma XJ, Jia B, Huang GY. Prevalence of congenital Heart Disease at live birth: an accurate assessment by echocardiographic screening. Acta Paediatr. 2013;102:397–402. https://doi.org/10.1111/apa.12170.
Zhao QM, Liu F, Wu L, Ma XJ, Niu C, Huang GY. Prevalence of congenital Heart Disease at live birth in China. J Pediatr. 2019;204:53–8. https://doi.org/10.1016/j.jpeds.2018.08.040.
Liu F, Yang YN, Xie X, et al. Prevalence of congenital Heart Disease in Xinjiang multi-ethnic region of China. PLoS ONE. 2015;10:e0133961. https://doi.org/10.1371/journal.pone.0133961.
Zaidi S, Brueckner M. Genetics and genomics of congenital Heart Disease. Circ Res. 2017;120:923–40. https://doi.org/10.1161/CIRCRESAHA.116.309140.
Thomford NE, Dzobo K, Yao NA, et al. Genomics and epigenomics of congenital heart defects: Expert review and lessons learned in Africa. OMICS. 2018;22:301–21. https://doi.org/10.1089/omi.2018.0033.
Rosa-Garrido M, Chapski DJ, Vondriska TM. Epigenomes in Cardiovascular Disease. Circ Res. 2018;122:1586–607. https://doi.org/10.1161/CIRCRESAHA.118.311597.
Courtney JA, Cnota JF, Jones HN. The role of abnormal placentation in congenital Heart Disease; cause, correlate, or consequence? Front Physiol. 2018;9:1045. https://doi.org/10.3389/fphys.2018.01045.
Puri K, Warshak CR, Habli MA, et al. Fetal somatic growth trajectory differs by type of congenital Heart Disease. Pediatr Res. 2017;83:669–76. https://doi.org/10.1038/pr.2017.275.
Laas E, Lelong N, Thieulin AC, et al. Preterm birth and congenital heart defects: a population-based study. Pediatrics. 2012;130:e829–37.
Jorgensen M, McPherson E, Zaleski C, Shivaram P, Cold C. Stillbirth: the heart of the matter. Am J Med Genet A. 2014;164A:691–9. https://doi.org/10.1002/ajmg.a.36366.
Auger N, Fraser WD, Healy-Profitos J, Arbour L. Association between preeclampsia and congenital heart defects. JAMA. 2015;314:1588–98. https://doi.org/10.1001/jama.2015.12505.
Russo MG, Paladini D, Pacileo G, et al. Changing spectrum and outcome of 705 fetal congenital Heart Disease cases: 12 years, experience in a third-level center. J Cardiovasc Med. 2008;9:910–5.
Kaasen A, Tuveng J, Heiberg A, Scott H, Haugen G. Correlation between prenatal ultrasound and autopsy findings: a study of second-trimester abortions. Ultrasound Obstet Gynecol. 2006;28:925–33. https://doi.org/10.1002/uog.3871.
International Society of Ultrasound in Obstetrics and Gynecology, Carvalho JS, Allan LD, et al. ISUOG Practice guidelines (updated): Sonographic screening examination of the fetal heart. Ultrasound Obstet Gynecol. 2013;41:348–59. https://doi.org/10.1002/uog.12403.
Zhang Y, Riehle-Colarusso T, Correa A, et al. Observed prevalence of congenital heart defects from a surveillance study in China. J Ultrasound Med. 2011;30:989–95. https://doi.org/10.7863/jum.2011.30.7.989.
Lees CC, Stampalija T, Baschat A, et al. ISUOG Practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56:298–312. https://doi.org/10.1002/uog.22134.
Fetal Echocardiography Task Force; American Institute of Ultrasound in Medicine Clinical Standards Committee; American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. AIUM practice guideline for the performance of fetal echocardiography. J Ultrasound Med. 2011;30:127–36. https://doi.org/10.7863/jum.2011.30.1.127.
Hedegaard H, Johnson RL. An Updated International Classification of Diseases, 10th revision, clinical modification (ICD-10-CM) Surveillance Case Definition for Injury hospitalizations. Natl Health Stat Report. 2019;125:1–8.
Li Z, Ren A, Zhang L, et al. Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China. Birth Defects Res a Clin Mol Teratol. 2006;76:237–40. https://doi.org/10.1002/bdra.20248.
Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr. 2008;153:807–13. https://doi.org/10.1016/j.jpeds.2008.05.059.
Fesslova V, Nava S, Villa L. Evolution and long-term outcome in cases with fetal diagnosis of congenital Heart Disease: Italian multicentre study. Fetal Cardiol Study Group Italian Soc Pediatr Cardiol. 1999;82:594–9.
Allan LD, Sharland GK, Milburn A, et al. Prospective diagnosis of 1,006 consecutive cases of congenital Heart Disease in the fetus. J Am College Cardiol. 1994;23:1452–8.
Tennstedt C, et al. Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart. 1999;82:34–9.
Levenson D. Talking about Down syndrome. Am J Med Genet A. 2009;149A:vii–viii. https://doi.org/10.1002/ajmg.a.32867.
DiGeorge AM. Discussions on a new concept of the cellular basis of immunity. J Pediatr. 1965;67:907.
Williams K, Carson J, Lo C. Genetics of congenital Heart Disease. Biomolecules. 2019;9:879. https://doi.org/10.3390/biom9120879.
Acknowledgements
This study was supported in part by the Key Project of Science and Technology Planning Project of Hubei Province (2010CDA038), the Hubei Province Natural Science Foundation (2012FFB01203), the Key Project of Hubei Province Natural Science Foundation (2011CDA012 and 2014CFA062), and the Research Foundation for Mental Hygiene (914–3280, 914–3257).
Funding
This study was supported in part by the Key Project of Science and Technology Planning Project of Hubei Province (2010CDA038), the Hubei Province Natural Science Foundation (2012FFB01203), the Key Project of Hubei Province Natural Science Foundation (2011CDA012 and 2014CFA062), and the New York State Research Foundation for Mental Hygiene (914–3280, 914–3257).
Author information
Authors and Affiliations
Consortia
Contributions
XC and NZ conceived and designed the research studies. XC, YlG, SZ, PC, YdG, QF, XZ, HH, XhL, XY, FY, CC, XsL, and the participants from the Chinese Consortium for Prenatal Ultrasound Screening of Congenital Heart Defects (CCPUSCHD) listed in Table S1 performed prenatal ultrasound screening, data collection, and postnatal confirmation. JL coordinated the CCPUSCHD. JL and NZ independently performed data analyses. XC, XD, WJ, and NZ. initiated manuscript drafting, and NZ finalized the manuscript and submitted it on behalf of the CCPUSCHD.
Corresponding authors
Ethics declarations
Conflict of interest
All authors have declared that there are no financial conflicts or conflicts of interest with other individuals or organizations.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Members of the Chinese Consortium for Prenatal Ultrasound Screening of Congenital Heart Defects are listed in Table S1.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chen, X., Zhao, S., Dong, X. et al. Incidence, distribution, disease spectrum, and genetic deficits of congenital heart defects in China: implementation of prenatal ultrasound screening identified 18,171 affected fetuses from 2,452,249 pregnancies. Cell Biosci 13, 229 (2023). https://doi.org/10.1186/s13578-023-01172-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13578-023-01172-7